Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

BioNTech (BNTX) is taking back-to-back clinical hits in its cancer vaccine pipeline, and the damage lands at a vulnerable moment: COVID-19 vaccine revenue has fallen 60% year over year, and the company remains unprofitable.

Two specific setbacks anchor the bearish case. First, a Phase 2 trial of autogene cevumeran has been halted. Second, BNT113 failed to meet its primary endpoint in head and neck cancer trials. Both programs sit at the center of the oncology story that investors have leaned on to offset shrinking pandemic-era sales.

The revenue picture compounds the problem. A 60% annual drop in COVID-19 vaccine sales removes the cash cushion that once funded pipeline spending, while the absence of profitability means there is no earnings floor beneath the stock. Interpretation: with the core business shrinking and two oncology readouts going the wrong way, BNTX's valuation now rests almost entirely on pipeline assets that have yet to deliver.

The source frames BNTX as suitable only for risk-tolerant investors, a clear signal that the thesis has shifted from steady growth to speculative upside. The pipeline is described as deep, so the setbacks do not erase the long-term option value, but they raise the bar for the next data release.